Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Guselkumab
Monoclonal Antibody · Immunosuppressant
Monoclonal AntibodyImmunosuppressant
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- BaricitinibSevereDatabaseDDInter
- CertolizumabSevereDatabaseDDInter
- CladribineSevereDatabaseDDInter
Mechanism
Guselkumab is a fully human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of IL-23 with high affinity and inhibits its interaction with the IL-23 receptor. This action secondarily reduces C-reactive protein (CRP), serum amyloid A (SAA), IL-6, and Th17 effector cytokines (IL-17A, IL-17F and IL-22) in active psoriatic arthritis.
Indications
Moderate to severe plaque psoriasis in patients who are candidates for systemic therapyTreatment of adult active plaque psoriasisPsoriatic arthritismoderate-to-severe plaque psoriasisactive psoriatic arthritis
Dosing
- Adult
- 100 mg by subcutaneous injection at 0 and 4 weeks, and every 8 weeks thereafter.
Pharmacokinetics
Peak effect
Approximately 5.5 days (Tmax) after a single 100-mg subcutaneous injection
Half-life
15–18 days
Bioavailability
49% after a single 100-mg subcutaneous injection
Metabolism
Exact metabolic pathway is unknown
Side effects
Common
Upper respiratory infections (nasopharyngitis)Injection-site reactions
Serious
- may increase risk of infections
Drug interactions
Baricitinib
Severe
Database
Drug interaction classified as: others
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Etanercept
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Fingolimod
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Golimumab
Severe
Database
Clinical effect not specified
Source: DDInter
Infliximab
Severe
Database
Clinical effect not specified
Source: DDInter
Leflunomide
Severe
Database
Clinical effect not specified
Source: DDInter
Measles Virus Vaccine Live Attenuated
Severe
Database
Clinical effect not specified
Source: DDInter
Mumps Virus Strain B Level Jeryl Lynn Live Antigen
Severe
Database
Clinical effect not specified
Source: DDInter
Natalizumab
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other Monoclonal Antibody drugs
Ask House about Guselkumab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team